Skip to main content
. 2006 Sep 30;21(3):165–172. doi: 10.3904/kjim.2006.21.3.165

Table 2.

Outcomes of empirical antifungal therapy

graphic file with name kjim-21-165-i002.jpg

*Breakthrough fungal infections were one case of disseminated aspergillosis (brain and lung), one case of cerebral aspergillosis and two cases of invasive pulmonary aspergillosis (IPA) in the itraconazole group, and two cases of IPA in the amphotericin B deoxycholate group.